Gonadotropin-releasing hormone (GnRH) analogues

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Metastatic Castration-Resistant Prostate CancerMetastatic Neuroendocrine Prostate Cancer

Phase 1

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruitingNCT06379217

Novartis PharmaceuticalsMetastatic Neuroendocrine Prostate Cancer

Start: 2024-07-29End: 2026-08-27Updated: 2026-03-11

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

RecruitingNCT06531499

Novartis PharmaceuticalsMetastatic Castration-Resistant Prostate Cancer

Start: 2024-11-11End: 2028-11-24Target: 106Updated: 2025-12-31